XML 40 R30.htm IDEA: XBRL DOCUMENT v3.21.2
Revenue Recognition and Collaborative Arrangements (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Revenue Recognition and Collaborative Arrangements        
Total net revenue $ 97,862 $ 88,694 $ 284,186 $ 246,318
Royalty revenue from a related party        
Revenue Recognition and Collaborative Arrangements        
Total net revenue 97,862 88,694 284,186 236,318
Revenue from collaborative arrangements with a related party        
Revenue Recognition and Collaborative Arrangements        
Total net revenue 0 0 0 10,000
GSK        
Revenue Recognition and Collaborative Arrangements        
Total net revenue 97,862 88,694 284,186 246,318
GSK | Royalty revenue from a related party        
Revenue Recognition and Collaborative Arrangements        
Royalties from a related party 101,318 92,150 294,554 246,686
Less: amortization of capitalized fees paid to a related party (3,456) (3,456) (10,368) (10,368)
Total net revenue 97,862 88,694 284,186 236,318
GSK | RELVAR/BREO        
Revenue Recognition and Collaborative Arrangements        
Royalties from a related party 54,092 63,893 176,398 165,612
GSK | ANORO        
Revenue Recognition and Collaborative Arrangements        
Royalties from a related party 11,641 11,882 34,101 32,931
GSK | TRELEGY        
Revenue Recognition and Collaborative Arrangements        
Royalties from a related party 35,585 16,375 84,055 48,143
GSK | Revenue from collaborative arrangements with a related party | Strategic alliance - MABA program        
Revenue Recognition and Collaborative Arrangements        
Total net revenue $ 0 $ 0 $ 0 $ 10,000